Teladoc Health Stock Forecast, Price & News

Teladoc Health's stock was trading at $137.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TDOC stock has increased by 108.3% and is now trading at $286.23.
View which stocks have been most impacted by COVID-19.

29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 12 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Teladoc Health stock.
View analyst ratings for Teladoc Health or view MarketBeat's top 5 stock picks.

Wall Street analysts have given Teladoc Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Teladoc Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

106 employees have rated Teladoc Health CEO Jason Gorevic on Glassdoor.com. Jason Gorevic has an approval rating of 95% among Teladoc Health's employees. This puts Jason Gorevic in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Teladoc Health is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Teladoc Health.

Teladoc Health, Inc. (NYSE:TDOC) issued its earnings results on Wednesday, October, 28th. The health services provider reported ($0.43) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.10. The health services provider had revenue of $288.81 million for the quarter, compared to the consensus estimate of $281.54 million. Teladoc Health had a negative net margin of 12.71% and a negative trailing twelve-month return on equity of 6.15%.
View Teladoc Health's earnings history.

Teladoc Health updated its fourth quarter 2020 After-Hours earnings guidance on Tuesday, November, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $369-379 million, compared to the consensus revenue estimate of $347.16 million.

29 brokerages have issued 1-year price objectives for Teladoc Health's shares. Their forecasts range from $165.00 to $330.00. On average, they expect Teladoc Health's share price to reach $238.57 in the next twelve months. This suggests that the stock has a possible downside of 16.7%.
View analysts' price targets for Teladoc Health or view Wall Street analyst' top-rated stocks.

Some companies that are related to Teladoc Health include Medtronic (MDT), Amgen (AMGN), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Sanofi (SNY), AstraZeneca PLC (AZN.L) (AZN), GlaxoSmithKline (GSK), CSL (CSLLY), Intuitive Surgical (ISRG), Stryker (SYK), Gilead Sciences (GILD), Anthem (ANTM), Zoetis (ZTS), Becton, Dickinson and (BDX) and GlaxoSmithKline plc (GSK.L) (GSK).
View all of TDOC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Square (SQ), Shopify (SHOP), DocuSign (DOCU), salesforce.com (CRM), PayPal (PYPL) and Zoom Video Communications (ZM).

(TDOC) raised $112 million in an IPO on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Teladoc Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (0.39%), Ardevora Asset Management LLP (0.17%), Peregrine Capital Management LLC (0.13%), Westwood Management Corp IL (0.13%), Spence Asset Management (0.09%) and Zweig DiMenna Associates LLC (0.08%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Gabriel R Cappucci, Glen Tullman, Hemant Taneja, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen, Stephany Verstraete, William H Frist and Yulun Wang.
View institutional ownership trends for Teladoc Health.

TDOC stock was sold by a variety of institutional investors in the last quarter, including Westwood Management Corp IL, Zweig DiMenna Associates LLC, Moody Lynn & Lieberson LLC, Bainco International Investors, Avantax Advisory Services Inc., Hall Laurie J Trustee, Meridian Wealth Management LLC, and Traynor Capital Management Inc.. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Arnnon Geshuri, Daniel Trencher, David L Shedlarz, David William Sides, Gabriel R Cappucci, Glen Tullman, Hemant Taneja, Jason N Gorevic, Kenneth H Paulus, Lewis Levy, Mala Murthy, Michael Goldstein, Michelle Bucaria, Stephany Verstraete, William H Frist, and Yulun Wang.
View insider buying and selling activity for Teladoc Health or view top insider-selling stocks.

TDOC stock was purchased by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Spence Asset Management, Rhenman & Partners Asset Management AB, Strs Ohio, LaFleur & Godfrey LLC, Riverbridge Partners LLC, Hamilton Lane Advisors LLC, and Peregrine Capital Management LLC.
View insider buying and selling activity for Teladoc Health or or view top insider-buying stocks.

Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of TDOC stock can currently be purchased for approximately $286.23.

Teladoc Health has a market capitalization of $41.49 billion and generates $553.31 million in revenue each year. The health services provider earns $-98,860,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Teladoc Health employs 2,400 workers across the globe.

The official website for Teladoc Health is www.teladochealth.com.

Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]